Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.05−0.07 (-0.98%)
Close on Nov 20, 2026Market cap $363.92MP/E 13.6Yield –
Puma Biotechnology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Puma Biotechnology's revenue for the twelve months ending Jun 30, 2026 was $231.24M, down 2.9% year over year. For fiscal 2025 it was $228.37M, down 0.9% from the year before. The highest annual figure on record is $272.26M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.37M | -0.9% |
| FY2024 | Dec 31, 2024 | $230.47M | -2.2% |
| FY2023 | Dec 31, 2023 | $235.64M | +3.3% |
| FY2022 | Dec 31, 2022 | $228.03M | -9.9% |
| FY2021 | Dec 31, 2021 | $253.16M | +12.5% |
| FY2020 | Dec 31, 2020 | $225.11M | -17.3% |
| FY2019 | Dec 31, 2019 | $272.26M | +8.5% |
| FY2018 | Dec 31, 2018 | $250.99M | +806.6% |
| FY2017 | Dec 31, 2017 | $27.69M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.50M | +7.8% |
| Q1 FY2026 | Mar 31, 2026 | $44.81M | -2.6% |
| Q4 FY2025 | Dec 31, 2025 | $75.45M | +27.7% |
| Q3 FY2025 | Sep 30, 2025 | $54.48M | -32.4% |
| Q2 FY2025 | Jun 30, 2025 | $52.44M | +11.4% |
| Q1 FY2025 | Mar 31, 2025 | $46.01M | +5.1% |
| Q4 FY2024 | Dec 31, 2024 | $59.08M | -18.2% |
| Q3 FY2024 | Sep 30, 2024 | $80.54M | +43.5% |
| Q2 FY2024 | Jun 30, 2024 | $47.08M | -13.7% |
| Q1 FY2024 | Mar 31, 2024 | $43.77M | -17.1% |
| Q4 FY2023 | Dec 31, 2023 | $72.18M | +9.9% |
| Q3 FY2023 | Sep 30, 2023 | $56.12M | -1.7% |
| Q2 FY2023 | Jun 30, 2023 | $54.57M | -8.3% |
| Q1 FY2023 | Mar 31, 2023 | $52.78M | +15.4% |
| Q4 FY2022 | Dec 31, 2022 | $65.68M | +18.6% |
| Q3 FY2022 | Sep 30, 2022 | $57.10M | +23.5% |
| Q2 FY2022 | Jun 30, 2022 | $59.52M | +11.5% |
| Q1 FY2022 | Mar 31, 2022 | $45.74M | -53.4% |
| Q4 FY2021 | Dec 31, 2021 | $55.36M | +5.3% |
| Q3 FY2021 | Sep 30, 2021 | $46.25M | -8.9% |
| Q2 FY2021 | Jun 30, 2021 | $53.38M | -24.4% |
| Q1 FY2021 | Mar 31, 2021 | $98.17M | +91.7% |
| Q4 FY2020 | Dec 31, 2020 | $52.56M | -16.5% |
| Q3 FY2020 | Sep 30, 2020 | $50.75M | -9.9% |
| Q2 FY2020 | Jun 30, 2020 | $70.58M | +30.9% |
| Q1 FY2020 | Mar 31, 2020 | $51.22M | -48.3% |
| Q4 FY2019 | Dec 31, 2019 | $62.92M | -11.5% |
| Q3 FY2019 | Sep 30, 2019 | $56.35M | -10.0% |
| Q2 FY2019 | Jun 30, 2019 | $53.92M | +6.2% |
| Q1 FY2019 | Mar 31, 2019 | $99.07M | +48.9% |
| Q4 FY2018 | Dec 31, 2018 | $71.08M | +228.9% |
| Q3 FY2018 | Sep 30, 2018 | $62.63M | +930.6% |
| Q2 FY2018 | Jun 30, 2018 | $50.77M | – |
| Q1 FY2018 | Mar 31, 2018 | $66.52M | – |
| Q4 FY2017 | Dec 31, 2017 | $21.61M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.08M | – |
See a number that looks wrong?